The androgens are steroids that develop and maintain primary and secondary male sex characteristics. Androgens are derivatives of cyclopentanoperhydrophenanthrene. Endogenous androgens are C-19 steroids with a side chain at C-17, and with two angular methyl groups. Testosterone is the primary endogenous androgen. In their active form, all drugs in the class have a 17-beta hydroxy group. 17-alpha alkylation (methylTESTOSTERone) increases the pharmacologic activity per unit weight compared to testosterone when given orally. MethylTESTOSTERone, a synthetic derivative of testosterone, is an androgenic preparation given by the oral route in a capsule form. Each capsule contains 10 mg of MethylTESTOSTERone USP.
Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone:
Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy.
Hypogonadotropic hypogonadism (congenital or acquired) — idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty.
Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS).
Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field.
Media Articles Related to Android (Methyltestosterone)
Android Phones to Send Location Info in Emergencies
Source: MedPage Today Emergency Medicine [2016.08.03]
(MedPage Today) -- So far, feature available only in England and Estonia
Published Studies Related to Android (Methyltestosterone)
Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study. [2011.01]
This study evaluated safety and efficacy of esterified estrogens and methyltestosterone administered alone or in combination for the treatment of hot flashes in menopausal women. The 0.30-mg esterified estrogens and 0.30-mg methyltestosterone combination was the lowest effective dose, and our results are consistent with the known safety profile of estrogen and androgen combination products.
Effects of methyltestosterone on immunity against Salmonella Pullorum in dwarf chicks. [2009.12]
This study was conducted to determine effects of methyltestosterone on innate immunity and adaptive immunity against Salmonella Pullorum in dwarf chicks. In vivo experiment, comparisons of pathological sections, viable counts of bacteria, specific antibody levels, and subsets of T lymphocytes were set forth between chicks with or without 10(-7) M methyltestosterone treatment (2 d of age through 21 d of age) and challenged with 5 x 10(8) virulent Salmonella Pullorum (7 d of age), and in vitro experiment, phagocytic and killing abilities, reactive oxygen intermediate production, and reactive nitrogen intermediate production of monocytes-macrophages treated with high (10(-8) M/10(6) cell) or physiological (10(-14) M/10(6) cell) concentration of methyltestosterone were examined after Salmonella Pullorum infection...
Effects of the addition of methyltestosterone to combined hormone therapy with estrogens and progestogens on sexual energy and on orgasm in postmenopausal women. [2008.02]
OBJECTIVE: To evaluate the effect of the addition of methyltestosterone to estrogen and progestogen therapy on postmenopausal sexual energy and orgasm... CONCLUSION: Addition of methyltestosterone to CEE/MPA therapy may increase sexual energy, but might not affect the ability to obtain orgasm in sexual relations.
Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: a double-blind controlled pilot study. [2006.03]
OBJECTIVE: This study evaluated the augmentation of venlafaxine with hormone therapy in the treatment of postmenopausal depression. The hormones evaluated were estrogen (0.625 mg) in combination with medroxyprogesterone acetate (2.5 mg) and methyltestosterone (2.5 mg)... CONCLUSIONS: Methyltestosterone 2.5 mg had the highest effect size compared with placebo, but the high dropout rate prevented its efficacy from being determined. Estrogen plus medroxyprogesterone, combined with methyltestosterone or otherwise, demonstrated a trend toward increased efficacy of venlafaxine. Further larger-scale clinical trials are needed to elucidate the findings of this pilot study.
[Effects of growth hormone on anthropometric and metabolic parameters in android obesity] [2006.02]
The aim of the study was to evaluate the effect of GH on body weight, body composition and cardiovascular risk factors in android obese men. Forty non-diabetic subjects aged 20 to 50 years-old with android obesity (WHR > 1) were divided in two groups, on a prospective randomized double-blind basis to receive treatment with GH (0.050 U/kg/day) or placebo for three months...
Clinical Trials Related to Android (Methyltestosterone)
Fluid Intake Application to Reduce Kidney Stone Risks [Enrolling by invitation]
Medtronic Minimed Overnight Closed-Loop System [Completed]
To test the function and safety of the Medtronic Overnight Closed Loop (OCL) System in a
closely monitored 12 hour overnight inpatient study. Once the safety of the device has been
validated we will move the study to an outpatient diabetes camp setting. The camp setting
will allow us to obtain pilot efficacy and safety data in a "real-life" environment.
We plan to compare the subject control nights to the subject nights on the OCL system to
assess the percent of sensor glucose readings in the target range of 70-150 mg/dl. Based on
previous research, we anticipate that the use of the OCL system will contribute to a greater
percentage of sensor glucose readings in the target range.
Effect of Hula Hooping as Compared to Walking on Adipose Tissue Distribution, Metabolic Parameters and Adipose Tissue Gene Expression [Completed]
Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease [Recruiting]
Background: Long-term management of Parkinson's disease (PD) does not reach its full
potential due to lack of knowledge about disease progression. The Real-PD study aim to
evaluate the feasibility and compliance of usage of wearable sensors in PD patients in real
life. Moreover, an explorative analysis concerning activity level, medication intake and
mood will be done.
Methods: Overall, 1000 PD patients and 250 physiotherapist will be enrolled in this
observational study. Dutch PD patients will be recruited across the country and an
assessment will be performed using a short version of the Parkinson's Progression Markers
Initiative (PPMI) protocol. Moreover, participants will wear a set of medical devices
(Pebble Smartwatch, fall detector) and they will use a smartphone with The Fox Insight App
(Android app), 24/7, during 13 weeks. Primary measures of interest are: 1) physical
activity, falls and tremor, measured by the axial accelerometers embedded in the Pebble
watch and fall detector; and 2) medication intake and mood reports measured by patients'
self-report in the Android app. To measure motor impact, an assessment will be performed by
physiotherapists who are all Unified Parkinson's disease rating scale - (MDS-UPDRS)
Discussion: Management of PD patients is complex and appears to be a challenging task for
health care professionals. The main reason is the lack of knowledge in the disease pattern.
This issue could be solved by a long term follow-up of patients' during their everyday life,
and wearable medical devices can act as a way to collect data about every day life
activities. Therefore, the Real-PD study will be a first contribution in increasing the lack
of knowledge in disease progression, developing a new medical decision system and improving
PD patients' care.
Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion [Completed]
The purpose of this study is to look at how effective, safe, and well tolerated Intravitreal
Aflibercept Injection is in subjects with Central Retinal Vein Occlusion (CRVO) or
Proliferative Diabetic Retinopathy (PDR).
Page last updated: 2016-08-03